Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients

N: Our objective was to confirm the efficacy and safety of edaravone in amyotrophic lateral sclerosis (ALS) patients. We conducted a 36-week confirmatory study, consisting of 12-week pre-observation period followed by 24-week treatment period. Patients received placebo or edaravone i.v. infusion ove...

Descripción completa

Detalles Bibliográficos
Autores principales: Abe, Koji, Itoyama, Yasuto, Sobue, Gen, Tsuji, Shoji, Aoki, Masashi, Doyu, Manabu, Hamada, Chikuma, Kondo, Kazuoki, Yoneoka, Takatomo, Akimoto, Makoto, Yoshino, Hiide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Informa Healthcare 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266079/
https://www.ncbi.nlm.nih.gov/pubmed/25286015
http://dx.doi.org/10.3109/21678421.2014.959024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266079/
https://www.ncbi.nlm.nih.gov/pubmed/25286015
http://dx.doi.org/10.3109/21678421.2014.959024

Ejemplares similares